[ad_1]
“GLP-1 isn’t just about hunger. It’s a metabolic regulator that affects insulin signalling, digestion, and muscle retention. While these drugs reduce caloric intake, they don’t distinguish between fat loss and muscle loss—a critical factor for long-term metabolic health,” explained Matias Muchnick, co-founder and CEO of NotCo.
This innovation from the AI-driven food tech company appeals to people who are wary about the side effects of GLP-1 medications.
[ad_2]
Source link